Switch to:
More From Other Websites
Earnings Call Notification Apr 26 2016
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May... Apr 26 2016
Management Council Apr 25 2016
ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the... Apr 19 2016
How Have India’s Industry and Services Sectors Performed? Apr 19 2016
China Takes a Breather as India Drives Growth in Asia Apr 07 2016
Investing in Indian Stocks: Active versus Passive Modes Apr 05 2016
Not a Good 1Q16 for Indian Stocks, but Is the Tide Turning? Apr 05 2016
Cutispharma, Dr. Reddy's Laboratories Announce Partnership Apr 05 2016
Dr. Reddy's Acquires Anticancer Drug Rights from Eisai Apr 01 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S,... Mar 31 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain... Mar 31 2016
Dr Reddy's Collaborates with XenoPort for Psoriasis Drug Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829 Mar 28 2016
Dr. Reddy’s and TR-Pharm Announce Strategic Collaboration in Turkey Mar 11 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK